ASND vs LKFT
Ascendis Pharma A/S and Galapagos NV, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ASND | LKFT |
|---|---|---|
| Revenue | €720.1M | €1.1B |
| Net income | €-228.0M | €320.9M |
| Gross margin | 86.8% | 97.3% |
| Net margin | −31.7% | 28.9% |
| Return on equity | — | — |
| Diluted EPS | −€3.76 | €4.87 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | €-469.8M | €-271.2M |
| Equity | — | — |
| Net debt / equity | — | — |
| Current ratio | 1.04× | 20.15× |
| Revenue CAGR 5y | 153.0% | 18.4% |
| Profit CAGR 5y | — | — |
LKFT bills 1.5× the revenue of ASND, and ASND closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | ASND | LKFT |
|---|---|---|
| FY2025 | €720.1M | €1.1B |
| FY2024 | €363.6M | €275.6M |
| FY2023 | €266.7M | €239.7M |
| FY2022 | €51.2M | €241.2M |
| FY2021 | €7.8M | €234.4M |
| FY2020 | €7.0M | €478.1M |
| FY2019 | €13.4M | €834.9M |
| FY2018 | €10.6M | €278.7M |
| FY2017 | €1.5M | €127.1M |
| FY2016 | €4.6M | €129.5M |
Net income by year
Bottom line
| Fiscal year | ASND | LKFT |
|---|---|---|
| FY2025 | €-228.0M | €320.9M |
| FY2024 | €-378.1M | €74.1M |
| FY2023 | €-481.4M | €211.7M |
| FY2022 | €-583.2M | €-218.0M |
| FY2021 | €-383.6M | €-103.2M |
| FY2020 | €-419.0M | €-305.4M |
| FY2019 | €-218.0M | €149.8M |
| FY2018 | €-130.1M | €-29.3M |
| FY2017 | €-123.9M | €-115.7M |
| FY2016 | €-68.5M | €54.0M |
Advertisement
AdSense · Rectangle 336×280